{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:25:51Z","timestamp":1794306351766,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.euo.2023.10.015","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:53:55Z","timestamp":1699005235000},"page":"786-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2911","authenticated-orcid":false,"given":"Bram C.","family":"Agema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.J.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mano","family":"Viskil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khrystany T.","family":"Isebia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha J.","family":"de Neijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan D.T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.10.015_b0005","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euo.2023.10.015_b0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.10.015_b0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2023.10.015_b0020","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0025","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2012.07.008","article-title":"Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study","volume":"49","author":"Dieras","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.10.015_b0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-17-2336","article-title":"Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients","volume":"24","author":"Belderbos","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.10.015_b0040","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s40262-022-01159-6","article-title":"Influence of darolutamide on cabazitaxel systemic exposure","volume":"61","author":"Buck","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.euo.2023.10.015_b0045","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1158\/1078-0432.CCR-16-2110","article-title":"Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study","volume":"23","author":"Nieuweboer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.10.015_b0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2022.09.032","article-title":"CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients","volume":"177","author":"Isebia","year":"2022","journal-title":"Eur J Cancer"},{"issue":"29(10)","key":"10.1016\/j.euo.2023.10.015_b0055","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1078-0432.CCR-22-3360","article-title":"Randomized phase 2 cabazitaxel dose individualization and neutropenia prevention trial (CAINTA) in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Omlin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.10.015_b0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","article-title":"Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding","volume":"59","author":"de Bruijn","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.euo.2023.10.015_b0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00280-012-2058-9","article-title":"Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors","volume":"71","author":"Ferron","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.euo.2023.10.015_b0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","article-title":"Covariate pharmacokinetic model building in oncology and its potential clinical relevance","volume":"14","author":"Joerger","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.euo.2023.10.015_b0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.euo.2023.10.015_b0080","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0085","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","article-title":"Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs","volume":"12","author":"Kloft","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2023.10.015_b0090","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"10.1016\/j.euo.2023.10.015_b0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2023.10.015_b0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/ph14020119","article-title":"Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors","volume":"14","author":"van Eerden","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.euo.2023.10.015_b0105","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/cancers13061284","article-title":"Pain Progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): a post hoc analysis of the PROSELICA study","volume":"13","author":"Delanoy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2023.10.015_b0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2019.10.029","article-title":"Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials","volume":"125","author":"Robbrecht","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2023.10.015_b0115","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2023.10.015_b0120","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0125","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jjco\/hyz108","article-title":"Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study","volume":"49","author":"Suzuki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221100022","article-title":"Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer","volume":"14","author":"Meisel","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euo.2023.10.015_b0135","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/bjc.2017.91","article-title":"Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer","volume":"116","author":"Janssen","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2023.10.015_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","article-title":"The current state of serum biomarkers of hepatotoxicity","volume":"245","author":"Ozer","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.euo.2023.10.015_b0145","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1215\/15228517-2008-120","article-title":"Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors","volume":"11","author":"Armstrong","year":"2009","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.euo.2023.10.015_b0150","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1245\/s10434-009-0523-4","article-title":"Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C","volume":"16","author":"Lambert","year":"2009","journal-title":"Ann Surg Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:36:13Z","timestamp":1794303373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2588931123002316"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}